×

Sarepta's big FDA win

5:51 PM ET Mon, 19 Sept 2016

Ed Kaye, Sarepta Therapeutics interim CEO, speaks to CNBC's Meg Tirrell about what's next for the company following FDA's recent approval of muscular dystrophy drug eteplirsen.